It’s been quite a while since I talked about ex-vivo lung perfusion, but this was an interesting advance I saw posted a few days ago from the Pulmonary Fibrosis News website.
This actually improves on existing ex-vivo lung perfusion (EVLP) technology by using gene & cell therapy to rehabilitate & repair lungs that would otherwise be unsuitable for transplant.
This Business Wire press release gives more information on the companies involved & this exciting news.
Hopefully the successes of these companies in Toronto will soon be crossing the border to us soon.
(I know my transplant center uses Ex-Vivo technology with a rehabilitative solution, but it’s not used in all cases & it currently has limits as to the damage that can be repaired with the solution.)
For further reading on EVLP please see these past blog posts:
There’s also this article from The Daily Mail on how one transplant recipient has praised the Ex-Vivo system & given an account of how she was helped by the technology.